Revista Pediatría de Atención Primaria 111

M.ª Ángeles Suárez Rodríguez, et al . Dislipemias y alteración de la lipoproteína A. Prevención de la enfermedad aterosclerótica Rev Pediatr Aten Primaria. 2026;28:335-9 ISSN: 1139-7632 • www.pap.es 339 adulthood. Circulation. 2023;147(1):23-31. https:// doi.org/10.1161/CIRCULATIONAHA.122.060667 7. Loh WJ, Pang J, Chakraborty A, Ward NC, Chan DC, Hooper AJ, et al. Cascade testing of children and ado- lescents for elevated Lp(a) in pedigrees with familial hypercholesterolemia. J Clin Lipidol. 2024;18:33-37. https://doi.org/10.1016/j.jacl.2023.11.007 8. KoschinskyML, Bajaj A, BoffaMB, DixonDL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18:e308-e319. https://doi.org/10.1016/j.jacl.2024.03.001 9. Catapano AL, Daccord M, Damato E, Humphries SE, Neely RDG, Nordestgaard BG, et al. How should pu- blic health recommendations address Lp(a) measu- rement, a causative risk factor for cardiovascular di- sease (CVD)? Atherosclerosis. 2022;349:136-43. https://doi.org/10.1016/j.atherosclerosis. 2022.02.013 10. Delgado-Lista J. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis: literature review and recommendations for clinical practice. Clin Investig Arterioscler. 2024;36(4):243-66. https://doi.org/10.1016/j.arteri.2024.03.002 11. Reyes Soffer G. High lipoprotein(a): actionable strate- gies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18:100651. https://doi.org/10.1016/j.ajpc.2024.100651 12. Moráis López A, Lama More RA, Dalmau Serra J; Comité de Nutrición de la AEP. Hipercolesterolemia. Abordaje terapéutico. An Pediatr (Barc). 2009;70(5):488-96. https://doi.org/10.1016/j.anpedi.2009.02.005 13. Ruffini O’Brien S. Thrombophilia testing in children and Adolescents. En: UpToDate [en línea] [consulta- do el 17/09/2026]. Disponible en www.uptodate. com/contents/thrombophilia-testing-in-children- and-adolescents